Keeping patients out of care facilities--- clozapine rescues Parkinson's patients with troublesome psychosis unresponsive to quetiapine and pimavanserin

被引：0
|
作者：
Iseringhausen, J.
Riboldi, G.
Astudillo, K.
Frucht, S.
机构：
来源：
MOVEMENT DISORDERS | 2023年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
1909
引用
收藏
页码：S837 / S837
页数：1
相关论文
共 50 条
  • [31] Risk of long-term care admissions among Medicare beneficiaries treated with pimavanserin or quetiapine for Parkinson's disease psychosis in USA: a retrospective administrative claims database analysis
    Rajagopalan, Krithika
    Rashid, Nazia
    Doshi, Dilesh
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2024, 13 (01)
  • [32] Naturalistic long term follow-up of psychotic Parkinson's disease patients treated with either clozapine or quetiapine
    Klein, C.
    Prokhorov, T.
    Dobronevsky, E.
    Miniovich, A.
    Rabey, J. M.
    MOVEMENT DISORDERS, 2007, 22 : S152 - S153
  • [33] Falls and Fractures in Patients with Parkinson’s Disease-Related Psychosis Treated with Pimavanserin vs Atypical Antipsychotics: A Cohort Study
    J. Bradley Layton
    Joan Forns
    Mary Ellen Turner
    Colleen Dempsey
    Jennifer L. Bartsch
    Mary S. Anthony
    Heather E. Danysh
    Mary E. Ritchey
    George Demos
    Drugs - Real World Outcomes, 2022, 9 : 9 - 22
  • [34] Mortality in Patients with Parkinson’s Disease-Related Psychosis Treated with Pimavanserin Compared with Other Atypical Antipsychotics: A Cohort Study
    J. Bradley Layton
    Joan Forns
    Lisa J. McQuay
    Heather E. Danysh
    Colleen Dempsey
    Mary S. Anthony
    Mary Ellen Turner
    Drug Safety, 2023, 46 : 195 - 208
  • [35] Efficacy results of pimavanserin from a multi-center, open-label extension study in Parkinson's disease psychosis patients
    Isaacson, Stuart H.
    Ballard, Clive G.
    Kreitzman, David L.
    Coate, Bruce
    Norton, James C.
    Fernandez, Hubert H.
    Ilic, Tihomir V.
    Azulay, Jean-Philippe
    Ferreira, Joaquim J.
    Abler, Victor
    Stankovic, Srdjan
    PARKINSONISM & RELATED DISORDERS, 2021, 87 : 25 - 31
  • [36] ER Visits and Hospitalizations Among Patients Treated with Pimavanserin or Other-AAPs for Parkinson's Disease Psychosis: Analysis of Medicare beneficiaries
    Kumar, S.
    Rashid, N.
    Doshi, D.
    Rajagopalan, K.
    MOVEMENT DISORDERS, 2022, 37 : S369 - S369
  • [37] Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes
    Rich, SS
    Friedman, JH
    Ott, BR
    JOURNAL OF CLINICAL PSYCHIATRY, 1995, 56 (12) : 556 - 559
  • [38] Safety assessment of pimavanserin in Parkinson's disease psychosis patients: Evidence from a systematic review and meta-analysis of randomized controlled trials
    Bano, G.
    Sharma, A.
    MOVEMENT DISORDERS, 2023, 38 : S230 - S230
  • [39] Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial (vol 383, pg 533, 2014)
    Cummings, J.
    Isaacson, S.
    Mills, R.
    LANCET, 2014, 384 (9937): : 28 - 28
  • [40] Treatment Patterns With Antipsychotics in Long-Term Care Patients With Parkinson's Disease Psychosis
    Rashid, Nazia
    Shim, Andrew
    Andes, Sherry
    Quale, Sonja
    Abler, Victor
    JOURNAL OF APPLIED GERONTOLOGY, 2022, 41 (01) : 198 - 206
12345